GlassScriptPhysician profile
Sergio G Thal
NPI 1568591006
$11,966.64
in general payments reported to CMS, 2019-2025
24 companies · $1,027 in 2025
The $1,027 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,725 · 2020: $178 · 2021: $4,133 · 2022: $736 · 2023: $1,483 · 2024: $2,686 · 2025: $1,027.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,910 · Travel and Lodging: $1,286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,909.59 |
| Travel and Lodging | $1,285.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $5,468.86 | 2021-2025 | Micra, Selectsecure, Pulseselect |
| Abbott Laboratories | $2,588.32 | 2019-2025 | Aveir, Ensite, Gallant |
| Biosense Webster, INC. | $1,285.36 | 2019-2025 | Carto 3 |
| Janssen Pharmaceuticals, INC | $509.33 | 2019-2024 | Xarelto |
| Medtronic Vascular, INC. | $463.39 | 2019 | |
| Boston Scientific Corporation | $296.08 | 2022-2025 | Farapulse |
| Impulse Dynamics (USA) INC. | $276.49 | 2019-2024 | Optimizer, Optimizer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $270.37 | 2019-2022 | |
| Abiomed | $167.59 | 2019-2024 | Impella |
| Amgen INC. | $99.17 | 2019-2023 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $92.99 | 2019-2024 | Eliquis |
| Pfizer INC. | $76.64 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.30 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $53.39 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $52.96 | 2019-2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $39.87 | 2025 | Nexletol |
| Regeneron Healthcare Solutions, INC. | $32.13 | 2019 | |
| Philips North America LLC | $29.60 | 2019 | |
| Edwards Lifesciences Corporation | $25.12 | 2021 | |
| Atricure, INC. | $17.30 | 2023 | |
| Merck Sharp & Dohme LLC | $15.22 | 2023 | Verquvo |
| Lundbeck LLC | $14.77 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.77 | 2022 | |
| Novo Nordisk INC | $13.62 | 2024 | Rybelsus, Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sergio Thal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.